The Long Run with Luke Timmerman Ep151: Shelley Force Aldred and Nathan Trinklein on Bispecific Antibodies for Cancer
Dec 26, 2023
Shelley Force Alderd and Nathan Trinklein talk about developing bispecific antibodies for cancer, discussing their journey from academia to entrepreneurship, the mechanism of action of T-cell engagers, challenges in developing therapies for solid tumors, and the importance of strategic company structuring for new drug candidates.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8
Introduction
00:00 • 2min
Exploring the Versatility and Innovation of Bi-Specific Antibodies in Biotech
01:44 • 3min
Journey from Academia to Entrepreneurship
04:22 • 17min
Evolution of Tineo Biome to Therapeutic Antibodies
21:05 • 8min
Exploring T-cell Engagers and the Balancing Act of Immune Cell Activation
29:01 • 3min
Developing Bispecific Antibodies for Cancer Treatment
32:05 • 14min
Advancements in Bi-Specific Antibodies for Solid Tumors
45:37 • 15min
Selective Venture Investment and Strategic Board Formation for Future Growth
01:01:01 • 3min